AFP ≥400 ng/mL
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
AFP ≥400 ng/mL is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing AFP ≥400 ng/mL drugs below.
Search AFP ≥400 ng/mL Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting AFP ≥400 ng/mL
| Drug | Company | Therapeutic Area |
|---|---|---|
| CYRAMZA | Eli Lilly | Oncology |
AFP ≥400 ng/mL Indications
Gastric Cancer Gastroesophageal Junction Adenocarcinoma Non-Small Cell Lung Cancer Colorectal Cancer Hepatocellular Carcinoma